Durham-based venture capital firm Hatteras Venture Partners traveled to New York for its latest investment.
Hatteras is one of three new investors participating in a $12 million Series B round raised by Coferon, a biotechnology firm/
Also investing were MedImmune Ventures and Ascent Biomedical Ventures.
As part of the deal, Dr. Colin Goddard, former chief executive officer of OSI Pharmaceuticals, was named chairman and CEO of Coferon. OSI was acquired for $4 billion in 2010 by Astellas Pharma.
Coferon has developed proprietary technology in which its “bioorthologonal linker chemistry” delivers small molecules in parts that are designed to self assemble once inside a targeted cell in order to deliver therapeutics.